Aligos Therapeutics Inc
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly mo… Read more
Aligos Therapeutics Inc (ALGS) - Total Liabilities
Latest total liabilities as of September 2025: $37.93 Million USD
Based on the latest financial reports, Aligos Therapeutics Inc (ALGS) has total liabilities worth $37.93 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Aligos Therapeutics Inc - Total Liabilities Trend (2018–2025)
This chart illustrates how Aligos Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Aligos Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Aligos Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
374Water Inc. Common Stock
NASDAQ:SCWO
|
USA | $4.87 Million |
|
Research Frontiers Incorporated
NASDAQ:REFR
|
USA | $1.27 Million |
|
Perintis Triniti Properti PT
JK:TRIN
|
Indonesia | Rp1.82 Trillion |
|
Cavatina Holding S.A.
WAR:CAV
|
Poland | zł2.70 Billion |
|
Samkee Automotive Co. Ltd
KQ:122350
|
Korea | ₩523.78 Billion |
|
TransAct Technologies Incorporated
NASDAQ:TACT
|
USA | $13.21 Million |
Liability Composition Analysis (2018–2025)
This chart breaks down Aligos Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.70 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.53 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.35 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Aligos Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Aligos Therapeutics Inc (2018–2025)
The table below shows the annual total liabilities of Aligos Therapeutics Inc from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $34.99 Million | -64.68% |
| 2024-12-31 | $99.07 Million | +66.65% |
| 2023-12-31 | $59.45 Million | +38.92% |
| 2022-12-31 | $42.79 Million | -15.49% |
| 2021-12-31 | $50.64 Million | +11.88% |
| 2020-12-31 | $45.26 Million | -78.59% |
| 2019-12-31 | $211.41 Million | +74.03% |
| 2018-12-31 | $121.48 Million | -- |